RSV (respiratory syncytial virus) is a common virus that can cause upper and lower respiratory tract infection, particularly in young infants and older adults. Symptoms range from mild cold-like symptoms to severe conditions such as bronchiolitis and pneumonia.
The virus is highly contagious and spreads through respiratory droplets when an infected person coughs or sneezes.
Pregnant women: a single dose of Abrysvo® is recommended for use in pregnant women at 28–36 weeks gestation to protect their newborn infant. This is provided free on the National Immunisation Program.
Older adults: a single dose of RSV vaccine (either Abrysvo® or Arexvy®) is recommended to protect all people aged ≥75 years, Aboriginal and Torres Strait Islander people aged ≥60 years, and people with medical risk factors for severe RSV disease aged ≥60 years. A private prescription is required.
Infants: a single dose of Beyfortus™ (nirsevimab) is recommended before their 1st RSV season in young infants whose mothers did not receive RSV vaccine at least 2 weeks before delivery, and in young infants who are at increased risk of severe RSV disease, regardless of their mother’s vaccination status.
Children up to 24 months of age who have medical risk factors for severe RSV disease in their 2nd RSV season. The dose of Beyfortus™ for older children entering their 2nd RSV season is 200 mg, given as 2 intramuscular injections (2 × 1 mL of the 100 mg/mL formulation) at 2 different sites (preferably separate limbs, or else separated by 2.5 cm) during the same visit.
Immunisation Weekly Update: Treatment of rabies and Australian bat lyssavirus Influenza vaccination coverage data update Correct administration of RSV vaccine and antibody products Education Treatment of rabies and Australian bat lyssavirus Any patient who presents with potential rabies or Australian bat lyssavirus exposure should be immediately referred to a doctor…
Immunisation Weekly Update: Influenza update for health professionals HPV coverage rates continue to drop New measles alert for Sydney TGA safety update: administration of RSV immunisation products Register to contribute to FluTracking New resources: vaccination for people with immunocompromise New RACF vaccination toolkit tackles suboptimal vaccination rates Education Influenza update…
Immunisation Weekly Update: CESPHN national rank continues to improve for childhood vaccination coverage Change to NIP supply of measles-containing vaccines Measles alert for Sydney NSW residents urged to act as COVID levels rise on top of influenza Japanese encephalitis resources updated Education CESPHN national rank continues to improve for childhood…
Immunisation Weekly Update: Join the Immunisation Working Group Register for free QI activities: Vaccination Recall Programs DVA eligibility for RSV vaccine Maternal Abrysvo ® vaccination program success New National Immunisation Strategy COVID-19 updates Education Join the Immunisation Working Group Vaccination providers are invited to join our Immunisation Working Group to…
Immunisation Weekly Update: Cessation of MBS COVID-19 vaccine support items from 1 July 2025 2025 updates to anaphylaxis training RSV vaccine safety data and resources New NCIRS meningococcal vaccines FAQs resource Influenza vaccination coverage data update Changes to pharmacist vaccination programs Education Cessation of MBS COVID-19 vaccine support items from…
Immunisation Weekly Update: Stay up to date with measles Protecting your patients from the flu First clade 1b mpox case in Australia Remind your patients about RSV and maternal vaccinations in pregnancy New First Nations and childhood vaccination resources Stay up to date with measles Lunch and learn recording and…